OncoMatch/Clinical Trials/NCT06441994
Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer
Is NCT06441994 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PSW-1025 for prostate cancer.
Treatment: PSW-1025 — PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: androgen receptor signaling inhibitor (enzalutamide, apalutamide, dalortamide)
Inhibitors of androgen receptor signaling (enzalutamide, apalutamide, dalortamide, etc.)
Must have received: CYP17 inhibitor (abiraterone acetate)
Inhibitors of Cytochrome P450 17 (CYP 17) (abiraterone acetate)
Cannot have received: systemic antitumor therapy
Exception: excluding androgen receptor signaling inhibitors
Patients who received systemic antitumor therapy (e.g. chemotherapy, immunotherapy, biologic therapy such as monoclonal antibodies, excluding androgen receptor signaling inhibitors) within 4 weeks before enrollment
Cannot have received: radioligand therapy (radium chloride (Radium, 223Ra), 177Lu (Lutetium)-PSMA-617)
Patients who received radium chloride (Radium, 223Ra) or 177Lu (Lutetium)-PSMA-617 within 6 months before registration
Cannot have received: cytotoxic chemotherapy
Patients currently receiving treatment with other cytotoxic chemotherapy
Cannot have received: immunotherapy
Patients currently receiving treatment with other...immunotherapy
Cannot have received: radioligand therapy
Patients currently receiving treatment with other...radioligand therapy
Cannot have received: PARP inhibitor
Patients currently receiving treatment with...poly adenosine diphosphate-ribose polymerase (PARP) inhibitors
Cannot have received: AKT inhibitor
Patients currently receiving treatment with...AKT inhibitors
Cannot have received: investigational drug
Patients who received other investigational drugs within 5 weeks prior to enrollment
Lab requirements
Cardiac function
no clinically significant abnormal findings in electrocardiogram
Patients with no clinically significant abnormal findings in electrocardiogram, respiratory rate, and blood oxygen saturation within 30 days before the enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify